Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 195 entries
Sorted by: Best Match Show Resources per page
Claudin 1 Promotes Migration and Increases Sensitivity to Tamoxifen and Anticancer Drugs in Luminal-like Human Breast Cancer Cells MCF7.

Cancer investigation

Zhou B, Blanchard A, Wang N, Ma X, Han J, Schroedter I, Leygue E, Myal Y.
PMID: 26279089
Cancer Invest. 2015 Aug 17; Epub 2015 Aug 17.

Downregulation of claudin 1, a critical tight junction protein, has been correlated with increased invasiveness in breast cancer. However, recent studies suggest that claudin 1 contributes to the progression of some molecular subtypes of breast cancer. In this study,...

Cite
Zhou B, Blanchard A, Wang N, et al. Claudin 1 Promotes Migration and Increases Sensitivity to Tamoxifen and Anticancer Drugs in Luminal-like Human Breast Cancer Cells MCF7. Cancer Invest. 2015;
Zhou, B., Blanchard, A., Wang, N., Ma, X., Han, J., Schroedter, I., Leygue, E., & Myal, Y. (2015). Claudin 1 Promotes Migration and Increases Sensitivity to Tamoxifen and Anticancer Drugs in Luminal-like Human Breast Cancer Cells MCF7. Cancer investigation, .
Zhou, Bowen, et al. "Claudin 1 Promotes Migration and Increases Sensitivity to Tamoxifen and Anticancer Drugs in Luminal-like Human Breast Cancer Cells MCF7." Cancer investigation vol. (2015).
Zhou B, Blanchard A, Wang N, Ma X, Han J, Schroedter I, Leygue E, Myal Y. Claudin 1 Promotes Migration and Increases Sensitivity to Tamoxifen and Anticancer Drugs in Luminal-like Human Breast Cancer Cells MCF7. Cancer Invest. 2015 Aug 17; Epub 2015 Aug 17. PMID: 26279089.
Copy Download .nbib Format: NLM
BCR-ABL Mutations in Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors and Impact on Survival.

Cancer investigation

Pagnano KB, Bendit I, Boquimpani C, De Souza CA, Miranda EC, Zalcberg I, Larripa I, Nardinelli L, Silveira RA, Fogliatto L, Spector N, Funke V, Pasquini R, Hungria V, Sérgio Chiattone C, Clementino N, Conchon M, Moiraghi EB, Lopez JL, Pavlovsky C, Pavlovsky MA, Cervera EE, Meillon LA, Simões B, Hamerschlak N, Bozzano AH, Mayta E, Cortes J, Bengió 5 On Behalf Of Latin American Leukemia Net Lalnet RM.
PMID: 26279306
Cancer Invest. 2015 Aug 17; Epub 2015 Aug 17.

This is the largest Latin American study of BCR-ABL mutations in chronic myeloid leukemia (CML) patients, resistant to imatinib (IM). In 195/467 (41%) patients, mutations were detected. The most frequent mutation was T315I (n = 31, 16%). Progression-free (PFS)...

Cite
Pagnano KB, Bendit I, Boquimpani C, et al. BCR-ABL Mutations in Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors and Impact on Survival. Cancer Invest. 2015;
Pagnano, K. B., Bendit, I., Boquimpani, C., De Souza, C. A., Miranda, E. C., Zalcberg, I., Larripa, I., Nardinelli, L., Silveira, R. A., Fogliatto, L., Spector, N., Funke, V., Pasquini, R., Hungria, V., Sérgio Chiattone, C., Clementino, N., Conchon, M., Moiraghi, E. B., Lopez, J. L., Pavlovsky, C., Pavlovsky, M. A., Cervera, E. E., Meillon, L. A., Simões, B., Hamerschlak, N., Bozzano, A. H., Mayta, E., Cortes, J., & Bengió 5 On Behalf Of Latin American Leukemia Net Lalnet, R. M. (2015). BCR-ABL Mutations in Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors and Impact on Survival. Cancer investigation, .
Pagnano, Katia Borgia Barbosa, et al. "BCR-ABL Mutations in Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors and Impact on Survival." Cancer investigation vol. (2015).
Pagnano KB, Bendit I, Boquimpani C, De Souza CA, Miranda EC, Zalcberg I, Larripa I, Nardinelli L, Silveira RA, Fogliatto L, Spector N, Funke V, Pasquini R, Hungria V, Sérgio Chiattone C, Clementino N, Conchon M, Moiraghi EB, Lopez JL, Pavlovsky C, Pavlovsky MA, Cervera EE, Meillon LA, Simões B, Hamerschlak N, Bozzano AH, Mayta E, Cortes J, Bengió 5 On Behalf Of Latin American Leukemia Net Lalnet RM. BCR-ABL Mutations in Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors and Impact on Survival. Cancer Invest. 2015 Aug 17; Epub 2015 Aug 17. PMID: 26279306.
Copy Download .nbib Format: NLM
Docetaxel in Castration-Resistant Prostate Cancer: A Single-Centre Experience.

Cancer investigation

Detti B, Franceschini D, Saieva C, Di Brina L, Baki M, Meattini I, Di Cataldo V, Pasquetti EM, Furfaro I, Mancuso A, Simontacchi G, Livi L.
PMID: 26135542
Cancer Invest. 2015;33(7):329. doi: 10.3109/07357907.2015.1060063. Epub 2015 Jul 02.

No abstract available.

Cite
Detti B, Franceschini D, Saieva C, et al. Docetaxel in Castration-Resistant Prostate Cancer: A Single-Centre Experience. Cancer Invest. 2015;33(7):329doi: 10.3109/07357907.2015.1060063.
Detti, B., Franceschini, D., Saieva, C., Di Brina, L., Baki, M., Meattini, I., Di Cataldo, V., Pasquetti, E. M., Furfaro, I., Mancuso, A., Simontacchi, G., & Livi, L. (2015). Docetaxel in Castration-Resistant Prostate Cancer: A Single-Centre Experience. Cancer investigation, 33(7), 329. https://doi.org/10.3109/07357907.2015.1060063
Detti, Beatrice, et al. "Docetaxel in Castration-Resistant Prostate Cancer: A Single-Centre Experience." Cancer investigation vol. 33,7 (2015): 329. doi: https://doi.org/10.3109/07357907.2015.1060063
Detti B, Franceschini D, Saieva C, Di Brina L, Baki M, Meattini I, Di Cataldo V, Pasquetti EM, Furfaro I, Mancuso A, Simontacchi G, Livi L. Docetaxel in Castration-Resistant Prostate Cancer: A Single-Centre Experience. Cancer Invest. 2015;33(7):329. doi: 10.3109/07357907.2015.1060063. Epub 2015 Jul 02. PMID: 26135542.
Copy Download .nbib Format: NLM
[Knowledge on cancer derived from experimental cancer investigation].

Munchener medizinische Wochenschrift (1950)

DOMAGK G.
PMID: 12993052
Munch Med Wochenschr. 1952 Sep 12;94(37):1841-8.

No abstract available.

Cite
DOMAGK G. Welche Erkenntnisse über den Krebs vermittelt uns die experimentelle Krebsforschung? [Knowledge on cancer derived from experimental cancer investigation]. Munch Med Wochenschr. 1952;94(37):1841-8
DOMAGK, G. (1952). Welche Erkenntnisse über den Krebs vermittelt uns die experimentelle Krebsforschung? [Knowledge on cancer derived from experimental cancer investigation]. Munchener medizinische Wochenschrift (1950), 94(37), 1841-8.
DOMAGK, G. "Welche Erkenntnisse über den Krebs vermittelt uns die experimentelle Krebsforschung?" [Knowledge on cancer derived from experimental cancer investigation]. Munchener medizinische Wochenschrift (1950) vol. 94,37 (1952): 1841-8.
DOMAGK G. Welche Erkenntnisse über den Krebs vermittelt uns die experimentelle Krebsforschung? [Knowledge on cancer derived from experimental cancer investigation]. Munch Med Wochenschr. 1952 Sep 12;94(37):1841-8. Undetermined. PMID: 12993052.
Copy Download .nbib Format: NLM
Letter: "Prognostic value of initial tumor parameters after metastatic relapse: do not miss the tumoral stroma".

Cancer investigation

Lacout A, Thariat J, Marcy PY.
PMID: 22506656
Cancer Invest. 2012 Jul;30(6):493. doi: 10.3109/07357907.2012.679346. Epub 2012 Apr 17.

No abstract available.

Cite
Lacout A, Thariat J, Marcy PY. Letter: "Prognostic value of initial tumor parameters after metastatic relapse: do not miss the tumoral stroma". Cancer Invest. 2012;30(6):493doi: 10.3109/07357907.2012.679346.
Lacout, A., Thariat, J., & Marcy, P. Y. (2012). Letter: "Prognostic value of initial tumor parameters after metastatic relapse: do not miss the tumoral stroma". Cancer investigation, 30(6), 493. https://doi.org/10.3109/07357907.2012.679346
Lacout, Alexis, et al. "Letter: "Prognostic value of initial tumor parameters after metastatic relapse: do not miss the tumoral stroma"." Cancer investigation vol. 30,6 (2012): 493. doi: https://doi.org/10.3109/07357907.2012.679346
Lacout A, Thariat J, Marcy PY. Letter: "Prognostic value of initial tumor parameters after metastatic relapse: do not miss the tumoral stroma". Cancer Invest. 2012 Jul;30(6):493. doi: 10.3109/07357907.2012.679346. Epub 2012 Apr 17. PMID: 22506656.
Copy Download .nbib Format: NLM
[Decision-making in head and neck cancer: Investigation on the mode of presentation of files and composition of the multidisciplinary team meetings].

Bulletin du cancer

Saroul N, Massoubre J, Biau J, Pastourel R, Mom T, Dillies AF, Barthelemy I, Lapeyre M, Gilain L.
PMID: 28774423
Bull Cancer. 2017 Sep;104(9):812-814. doi: 10.1016/j.bulcan.2017.06.009. Epub 2017 Jul 31.

No abstract available.

Cite
Saroul N, Massoubre J, Biau J, et al. La prise de décision en cancérologie des voies aéro-digestives supérieures : enquête sur le mode de présentation des dossiers et sur la composition des réunions de concertations pluridisciplinaires. [Decision-making in head and neck cancer: Investigation on the mode of presentation of files and composition of the multidisciplinary team meetings]. Bull Cancer. 2017;104(9):812-814doi: 10.1016/j.bulcan.2017.06.009.
Saroul, N., Massoubre, J., Biau, J., Pastourel, R., Mom, T., Dillies, A. F., Barthelemy, I., Lapeyre, M., & Gilain, L. (2017). La prise de décision en cancérologie des voies aéro-digestives supérieures : enquête sur le mode de présentation des dossiers et sur la composition des réunions de concertations pluridisciplinaires. [Decision-making in head and neck cancer: Investigation on the mode of presentation of files and composition of the multidisciplinary team meetings]. Bulletin du cancer, 104(9), 812-814. https://doi.org/10.1016/j.bulcan.2017.06.009
Saroul, Nicolas, et al. "La prise de décision en cancérologie des voies aéro-digestives supérieures : enquête sur le mode de présentation des dossiers et sur la composition des réunions de concertations pluridisciplinaires." [Decision-making in head and neck cancer: Investigation on the mode of presentation of files and composition of the multidisciplinary team meetings]. Bulletin du cancer vol. 104,9 (2017): 812-814. doi: https://doi.org/10.1016/j.bulcan.2017.06.009
Saroul N, Massoubre J, Biau J, Pastourel R, Mom T, Dillies AF, Barthelemy I, Lapeyre M, Gilain L. La prise de décision en cancérologie des voies aéro-digestives supérieures : enquête sur le mode de présentation des dossiers et sur la composition des réunions de concertations pluridisciplinaires. [Decision-making in head and neck cancer: Investigation on the mode of presentation of files and composition of the multidisciplinary team meetings]. Bull Cancer. 2017 Sep;104(9):812-814. doi: 10.1016/j.bulcan.2017.06.009. Epub 2017 Jul 31. French. PMID: 28774423.
Copy Download .nbib Format: NLM
Next-generation sequencing: advances and applications in cancer diagnosis.

OncoTargets and therapy

Serratì S, De Summa S, Pilato B, Petriella D, Lacalamita R, Tommasi S, Pinto R.
PMID: 27980425
Onco Targets Ther. 2016 Dec 02;9:7355-7365. doi: 10.2147/OTT.S99807. eCollection 2016.

Technological advances have led to the introduction of next-generation sequencing (NGS) platforms in cancer investigation. NGS allows massive parallel sequencing that affords maximal tumor genomic assessment. NGS approaches are different, and concern DNA and RNA analysis. DNA sequencing includes...

Cite
Serratì S, De Summa S, Pilato B, et al. Next-generation sequencing: advances and applications in cancer diagnosis. Onco Targets Ther. 2016;9:7355-7365doi: 10.2147/OTT.S99807.
Serratì, S., De Summa, S., Pilato, B., Petriella, D., Lacalamita, R., Tommasi, S., & Pinto, R. (2016). Next-generation sequencing: advances and applications in cancer diagnosis. OncoTargets and therapy, 97355-7365. https://doi.org/10.2147/OTT.S99807
Serratì, Simona, et al. "Next-generation sequencing: advances and applications in cancer diagnosis." OncoTargets and therapy vol. 9 (2016): 7355-7365. doi: https://doi.org/10.2147/OTT.S99807
Serratì S, De Summa S, Pilato B, Petriella D, Lacalamita R, Tommasi S, Pinto R. Next-generation sequencing: advances and applications in cancer diagnosis. Onco Targets Ther. 2016 Dec 02;9:7355-7365. doi: 10.2147/OTT.S99807. eCollection 2016. PMID: 27980425; PMCID: PMC5144906.
Copy Download .nbib Format: NLM
Corrigendum.

Cancer investigation

[No authors listed]
PMID: 28055278
Cancer Invest. 2017 Jan 02;35(1):70. doi: 10.1080/07357907.2016.1260377. Epub 2017 Jan 05.

No abstract available.

Cite
Corrigendum. Cancer Invest. 2017;35(1):70doi: 10.1080/07357907.2016.1260377.
(2017). Corrigendum. Cancer investigation, 35(1), 70. https://doi.org/10.1080/07357907.2016.1260377
"Corrigendum." Cancer investigation vol. 35,1 (2017): 70. doi: https://doi.org/10.1080/07357907.2016.1260377
Corrigendum. Cancer Invest. 2017 Jan 02;35(1):70. doi: 10.1080/07357907.2016.1260377. Epub 2017 Jan 05. PMID: 28055278.
Copy Download .nbib Format: NLM
Development and comprehensive characterization of porcine hepatocellular carcinoma for translational liver cancer investigation.

Oncotarget

Gaba RC, Elkhadragy L, Boas FE, Chaki S, Chen HH, El-Kebir M, Garcia KD, Giurini EF, Guzman G, LoBianco FV, Neto MF, Newson JL, Qazi A, Regan M, Rund LA, Schwind RM, Stewart MC, Thomas FM, Whiteley HE, Wu J, Schook LB, Schachtschneider KM.
PMID: 32733642
Oncotarget. 2020 Jul 14;11(28):2686-2701. doi: 10.18632/oncotarget.27647. eCollection 2020 Jul 14.

Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide. New animal models that faithfully recapitulate human HCC phenotypes are required to address unmet clinical needs and advance standard-of-care therapeutics. This study utilized the Oncopig Cancer Model...

Cite
Gaba RC, Elkhadragy L, Boas FE, et al. Development and comprehensive characterization of porcine hepatocellular carcinoma for translational liver cancer investigation. Oncotarget. 2020;11(28):2686-2701doi: 10.18632/oncotarget.27647.
Gaba, R. C., Elkhadragy, L., Boas, F. E., Chaki, S., Chen, H. H., El-Kebir, M., Garcia, K. D., Giurini, E. F., Guzman, G., LoBianco, F. V., Neto, M. F., Newson, J. L., Qazi, A., Regan, M., Rund, L. A., Schwind, R. M., Stewart, M. C., Thomas, F. M., Whiteley, H. E., Wu, J., Schook, L. B., & Schachtschneider, K. M. (2020). Development and comprehensive characterization of porcine hepatocellular carcinoma for translational liver cancer investigation. Oncotarget, 11(28), 2686-2701. https://doi.org/10.18632/oncotarget.27647
Gaba, Ron C, et al. "Development and comprehensive characterization of porcine hepatocellular carcinoma for translational liver cancer investigation." Oncotarget vol. 11,28 (2020): 2686-2701. doi: https://doi.org/10.18632/oncotarget.27647
Gaba RC, Elkhadragy L, Boas FE, Chaki S, Chen HH, El-Kebir M, Garcia KD, Giurini EF, Guzman G, LoBianco FV, Neto MF, Newson JL, Qazi A, Regan M, Rund LA, Schwind RM, Stewart MC, Thomas FM, Whiteley HE, Wu J, Schook LB, Schachtschneider KM. Development and comprehensive characterization of porcine hepatocellular carcinoma for translational liver cancer investigation. Oncotarget. 2020 Jul 14;11(28):2686-2701. doi: 10.18632/oncotarget.27647. eCollection 2020 Jul 14. PMID: 32733642; PMCID: PMC7367657.
Copy Download .nbib Format: NLM
Treatment and Survival Disparities in the National Cancer Institute's Patterns of Care Study (1987-2017).

Cancer investigation

Penn DC, Baker M, Geiger AM, Harlan LC.
PMID: 30136865
Cancer Invest. 2018;36(6):319-329. doi: 10.1080/07357907.2018.1474894. Epub 2018 Aug 23.

BACKGROUND: Cancer health services research is a primary tool for analyzing the association between various factors, cancer health care delivery, and the resultant outcomes. To address disparities strategies must be developed to target factors that are related to differences...

Cite
Penn DC, Baker M, Geiger AM, et al. Treatment and Survival Disparities in the National Cancer Institute's Patterns of Care Study (1987-2017). Cancer Invest. 2018;36(6):319-329doi: 10.1080/07357907.2018.1474894.
Penn, D. C., Baker, M., Geiger, A. M., & Harlan, L. C. (2018). Treatment and Survival Disparities in the National Cancer Institute's Patterns of Care Study (1987-2017). Cancer investigation, 36(6), 319-329. https://doi.org/10.1080/07357907.2018.1474894
Penn, Dolly C, et al. "Treatment and Survival Disparities in the National Cancer Institute's Patterns of Care Study (1987-2017)." Cancer investigation vol. 36,6 (2018): 319-329. doi: https://doi.org/10.1080/07357907.2018.1474894
Penn DC, Baker M, Geiger AM, Harlan LC. Treatment and Survival Disparities in the National Cancer Institute's Patterns of Care Study (1987-2017). Cancer Invest. 2018;36(6):319-329. doi: 10.1080/07357907.2018.1474894. Epub 2018 Aug 23. PMID: 30136865; PMCID: PMC6295665.
Copy Download .nbib Format: NLM
Punicalagin promotes the apoptosis in human cervical cancer (ME-180) cells through mitochondrial pathway and by inhibiting the NF-kB signaling pathway.

Saudi journal of biological sciences

Zhang L, Chinnathambi A, Alharbi SA, Veeraraghavan VP, Mohan SK, Zhang G.
PMID: 32256171
Saudi J Biol Sci. 2020 Apr;27(4):1100-1106. doi: 10.1016/j.sjbs.2020.02.015. Epub 2020 Mar 04.

Increasing attention of plant derived therapeutic agents against cancer, investigating the anti-proliferative efficiency of plant derived chemicals have achieved increasing momentum for the design of anticancer drug. Punicalagin, dietary phytochemical altered the various cell signal transduction pathways associated with...

Cite
Zhang L, Chinnathambi A, Alharbi SA, et al. Punicalagin promotes the apoptosis in human cervical cancer (ME-180) cells through mitochondrial pathway and by inhibiting the NF-kB signaling pathway. Saudi J Biol Sci. 2020;27(4):1100-1106doi: 10.1016/j.sjbs.2020.02.015.
Zhang, L., Chinnathambi, A., Alharbi, S. A., Veeraraghavan, V. P., Mohan, S. K., & Zhang, G. (2020). Punicalagin promotes the apoptosis in human cervical cancer (ME-180) cells through mitochondrial pathway and by inhibiting the NF-kB signaling pathway. Saudi journal of biological sciences, 27(4), 1100-1106. https://doi.org/10.1016/j.sjbs.2020.02.015
Zhang, Li, et al. "Punicalagin promotes the apoptosis in human cervical cancer (ME-180) cells through mitochondrial pathway and by inhibiting the NF-kB signaling pathway." Saudi journal of biological sciences vol. 27,4 (2020): 1100-1106. doi: https://doi.org/10.1016/j.sjbs.2020.02.015
Zhang L, Chinnathambi A, Alharbi SA, Veeraraghavan VP, Mohan SK, Zhang G. Punicalagin promotes the apoptosis in human cervical cancer (ME-180) cells through mitochondrial pathway and by inhibiting the NF-kB signaling pathway. Saudi J Biol Sci. 2020 Apr;27(4):1100-1106. doi: 10.1016/j.sjbs.2020.02.015. Epub 2020 Mar 04. PMID: 32256171; PMCID: PMC7105651.
Copy Download .nbib Format: NLM
Health care reform.

Cancer investigation

Gelb RL.
PMID: 7583720
Cancer Invest. 1995;13(6):664-5. doi: 10.3109/07357909509024939.

No abstract available.

Cite
Gelb RL. Health care reform. Cancer Invest. 1995;13(6):664-5doi: 10.3109/07357909509024939.
Gelb, R. L. (1995). Health care reform. Cancer investigation, 13(6), 664-5. https://doi.org/10.3109/07357909509024939
Gelb, R L. "Health care reform." Cancer investigation vol. 13,6 (1995): 664-5. doi: https://doi.org/10.3109/07357909509024939
Gelb RL. Health care reform. Cancer Invest. 1995;13(6):664-5. doi: 10.3109/07357909509024939. PMID: 7583720.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 195 entries